CA
ABVX

Clearstead Advisors’s Abivax ABVX Stock Holding History

Clearstead Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.66K Buy
+65
New +$7.36K ﹤0.01% 2028
2026
Q1 		– Sell
-1,026
Closed -$138K – 2241
2025
Q4 		$138K Buy
+1,026
New +$112K ﹤0.01% 1026

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors's ABVX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Abivax (ABVX) in Q2 2026: 65 shares worth $8.66K. The stake represents ﹤0.01% of the portfolio and ranks #2028 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ABVX as recently as Q4 2025.

Clearstead Advisors first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $138K in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Clearstead Advisors held 65 shares of Abivax worth $8.66K as of Q2 2026.
  • Abivax was a new Clearstead Advisors position in Q2 2026.
  • Abivax made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2028 holding.
  • Clearstead Advisors first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Abivax position peaked at $138K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.